G6pd N126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease.

Christina SignorettiShun MatsumuraSamuel FatehiMelinee D'SilvaRajamma MathewFrancesca Isabelle CendaliAngelo D'AlessandroS M Shafiqul AlamVictor Garcia Joseph M Miano Sachin A Gupte

Published in: Journal of the American Heart Association (2024)

signaling, inflammation, thrombosis, and hypertrophic pulmonary artery remodeling in SU-treated rats. This suggests an increased risk of vascular endothelial cell growth factor receptor blocker-induced pulmonary hypertension in those carrying this G6PD variant.

Keyphrases

pulmonary hypertension
pulmonary artery
vascular endothelial growth factor
growth factor
high glucose
endothelial cells
pulmonary arterial hypertension
coronary artery
diabetic rats
oxidative stress
drug induced
pulmonary embolism
angiotensin converting enzyme